Form 6-K ARGENX SE For: Dec 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'
December 15, 2025 10:25 AM ESTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $1,085.00 price target on argenx SE (NASDAQ: ARGX).
The analyst comments "We caught up with ARGX following today's announcement regarding the discontinuation of efgartigimod's (anti-FcRn) thyroid eye disease (TED) pivotal study due to futility, which we view as reflective of the specific indication biology with minimal read-across to the Graves'... More



